Modern japanese approach to pancreatic cancer

Takao Ohtsuka, Masao Tanaka

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Principal clues to early diagnosis of pancreatic cancer including pancreatic duct dilation, diabetes, and intraductal papillary mucinous neoplasms are discussed, referring to Japanese contributions. The Japan Pancreas Society (JPS) has revised fourth edition of Clinical Guidelines for Management of Pancreatic Cancer, providing 51 clinical questionswith graded evidence-based recommendations in 2016, and diagnosis, chemotherapy, radiation therapy, surgical resection, adjuvant treatments, and supportive therapy are addressed. "Borderline resectable (BR)" pancreatic cancer is a new concept, and JPS makes two categories of BR pancreatic cancer such as involvement of only portal vein (BR-PV) and involvement of major artery (BR-A). Extended resection cannot be actively advocated in patients with pancreatic cancer in the present daily practice, because several prospective randomized trials did not confirm the survival benefit of extended resection compared to standard resection. The analysis using data of the JPS Pancreatic Cancer Registry indicates that the 5-year survival rate of patients after resection of pancreatic cancer has been significantly improved after the introduction of gemcitabine into Japan. More recently, a Japanese group has demonstrated that S-1 adjuvant chemotherapy is superior to gemcitabine. Recent great interest in Japan is to clarify the significance of neoadjuvant treatments in resectable and BR pancreatic cancer.

Original languageEnglish
Title of host publicationPancreatic Cancer
PublisherSpringer New York
Pages1169-1186
Number of pages18
ISBN (Electronic)9781493971930
ISBN (Print)9781493971916
DOIs
Publication statusPublished - Apr 11 2018

Fingerprint

Pancreatic Neoplasms
gemcitabine
Japan
Pancreas
Neoadjuvant Therapy
Pancreatic Ducts
Adjuvant Chemotherapy
Portal Vein
Early Detection of Cancer
Registries
Dilatation
Radiotherapy
Survival Rate
Arteries
Guidelines
Drug Therapy
Survival
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)

Cite this

Ohtsuka, T., & Tanaka, M. (2018). Modern japanese approach to pancreatic cancer. In Pancreatic Cancer (pp. 1169-1186). Springer New York. https://doi.org/10.1007/978-1-4939-7193-0_49

Modern japanese approach to pancreatic cancer. / Ohtsuka, Takao; Tanaka, Masao.

Pancreatic Cancer. Springer New York, 2018. p. 1169-1186.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ohtsuka, T & Tanaka, M 2018, Modern japanese approach to pancreatic cancer. in Pancreatic Cancer. Springer New York, pp. 1169-1186. https://doi.org/10.1007/978-1-4939-7193-0_49
Ohtsuka T, Tanaka M. Modern japanese approach to pancreatic cancer. In Pancreatic Cancer. Springer New York. 2018. p. 1169-1186 https://doi.org/10.1007/978-1-4939-7193-0_49
Ohtsuka, Takao ; Tanaka, Masao. / Modern japanese approach to pancreatic cancer. Pancreatic Cancer. Springer New York, 2018. pp. 1169-1186
@inbook{e7f599fa5fdf40289a872d54dd8de7bb,
title = "Modern japanese approach to pancreatic cancer",
abstract = "Principal clues to early diagnosis of pancreatic cancer including pancreatic duct dilation, diabetes, and intraductal papillary mucinous neoplasms are discussed, referring to Japanese contributions. The Japan Pancreas Society (JPS) has revised fourth edition of Clinical Guidelines for Management of Pancreatic Cancer, providing 51 clinical questionswith graded evidence-based recommendations in 2016, and diagnosis, chemotherapy, radiation therapy, surgical resection, adjuvant treatments, and supportive therapy are addressed. {"}Borderline resectable (BR){"} pancreatic cancer is a new concept, and JPS makes two categories of BR pancreatic cancer such as involvement of only portal vein (BR-PV) and involvement of major artery (BR-A). Extended resection cannot be actively advocated in patients with pancreatic cancer in the present daily practice, because several prospective randomized trials did not confirm the survival benefit of extended resection compared to standard resection. The analysis using data of the JPS Pancreatic Cancer Registry indicates that the 5-year survival rate of patients after resection of pancreatic cancer has been significantly improved after the introduction of gemcitabine into Japan. More recently, a Japanese group has demonstrated that S-1 adjuvant chemotherapy is superior to gemcitabine. Recent great interest in Japan is to clarify the significance of neoadjuvant treatments in resectable and BR pancreatic cancer.",
author = "Takao Ohtsuka and Masao Tanaka",
year = "2018",
month = "4",
day = "11",
doi = "10.1007/978-1-4939-7193-0_49",
language = "English",
isbn = "9781493971916",
pages = "1169--1186",
booktitle = "Pancreatic Cancer",
publisher = "Springer New York",
address = "United States",

}

TY - CHAP

T1 - Modern japanese approach to pancreatic cancer

AU - Ohtsuka, Takao

AU - Tanaka, Masao

PY - 2018/4/11

Y1 - 2018/4/11

N2 - Principal clues to early diagnosis of pancreatic cancer including pancreatic duct dilation, diabetes, and intraductal papillary mucinous neoplasms are discussed, referring to Japanese contributions. The Japan Pancreas Society (JPS) has revised fourth edition of Clinical Guidelines for Management of Pancreatic Cancer, providing 51 clinical questionswith graded evidence-based recommendations in 2016, and diagnosis, chemotherapy, radiation therapy, surgical resection, adjuvant treatments, and supportive therapy are addressed. "Borderline resectable (BR)" pancreatic cancer is a new concept, and JPS makes two categories of BR pancreatic cancer such as involvement of only portal vein (BR-PV) and involvement of major artery (BR-A). Extended resection cannot be actively advocated in patients with pancreatic cancer in the present daily practice, because several prospective randomized trials did not confirm the survival benefit of extended resection compared to standard resection. The analysis using data of the JPS Pancreatic Cancer Registry indicates that the 5-year survival rate of patients after resection of pancreatic cancer has been significantly improved after the introduction of gemcitabine into Japan. More recently, a Japanese group has demonstrated that S-1 adjuvant chemotherapy is superior to gemcitabine. Recent great interest in Japan is to clarify the significance of neoadjuvant treatments in resectable and BR pancreatic cancer.

AB - Principal clues to early diagnosis of pancreatic cancer including pancreatic duct dilation, diabetes, and intraductal papillary mucinous neoplasms are discussed, referring to Japanese contributions. The Japan Pancreas Society (JPS) has revised fourth edition of Clinical Guidelines for Management of Pancreatic Cancer, providing 51 clinical questionswith graded evidence-based recommendations in 2016, and diagnosis, chemotherapy, radiation therapy, surgical resection, adjuvant treatments, and supportive therapy are addressed. "Borderline resectable (BR)" pancreatic cancer is a new concept, and JPS makes two categories of BR pancreatic cancer such as involvement of only portal vein (BR-PV) and involvement of major artery (BR-A). Extended resection cannot be actively advocated in patients with pancreatic cancer in the present daily practice, because several prospective randomized trials did not confirm the survival benefit of extended resection compared to standard resection. The analysis using data of the JPS Pancreatic Cancer Registry indicates that the 5-year survival rate of patients after resection of pancreatic cancer has been significantly improved after the introduction of gemcitabine into Japan. More recently, a Japanese group has demonstrated that S-1 adjuvant chemotherapy is superior to gemcitabine. Recent great interest in Japan is to clarify the significance of neoadjuvant treatments in resectable and BR pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=85054044464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054044464&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-7193-0_49

DO - 10.1007/978-1-4939-7193-0_49

M3 - Chapter

AN - SCOPUS:85054044464

SN - 9781493971916

SP - 1169

EP - 1186

BT - Pancreatic Cancer

PB - Springer New York

ER -